Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration today cautioned patients and healthcare providers against changing treatments based on results from pharmacogenetic tests with unproven indications that the agency hasn't approved for marketing.

The FDA further indicated it is looking into companies selling PGx testing for unapproved uses and may take compliance action against these firms.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.